@2024 Afarand., IRAN
ISSN: 2252-0805 The Horizon of Medical Sciences 2018;24(1):1-6
ISSN: 2252-0805 The Horizon of Medical Sciences 2018;24(1):1-6
Antifungal Effect of Lipopeptide Compounds Produced by Bacillus amyloliquefaciens M13RW01
ARTICLE INFO
Article Type
Original ResearchAuthors
Aghaali Marnani M. (1)Madani M. (*)
(*) Microbiology Department, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
(1) Falavarjan Branch, Islamic Azad University, Isfahan, Iran
Correspondence
Article History
Received: March 6, 2017Accepted: November 1, 2017
ePublished: January 11, 2018
ABSTRACT
Aims
Bacillus amyloliquefaciens lipopeptide are made of amino acids and fatty acid chain, and have many antifungal activities against several important pathogenic yeasts. The present research was carried out with the aim of extraction and evaluation of antifungal effect of lipopeptide compounds produced by Esfahan native Bacillus amyloliquefaciens M13RW01 against Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis.
Materials & Methods In this experimental study, Bacillus amyloliquefaciens M13RW01 was cultured in modified Peptone-Glucose-Yeast extract medium (PGY) for 72 hours. Then, the lipopeptide compounds produced in the medium by precipitation with HCl 6M were extracted and dissolved in methanol (50% water; 50% methanol). The antifungal activity of lipopeptide compounds against 5 species of Candida was investigated by well diffusion method, Minimum Inhibitory Concentration (MIC), and Minimum Fungal Concentration (MFC). Also, germ tube production by Candida albicans in tube containing lipopeptide was investigated.
Conclusion The Bacillus amyloliquefaciens M13RW01 lipopeptide metabolites inhibited germ tube production in all C. albicans yeasts, but no inhibitory or fatal effect was observed on other species of Candida. Inhibition zone was not observed around the wells; in all dilutions, Candida yeasts grew. Therefore, minimal inhibitory concentration and minimal fungicidal concentration were not determined.
Materials & Methods In this experimental study, Bacillus amyloliquefaciens M13RW01 was cultured in modified Peptone-Glucose-Yeast extract medium (PGY) for 72 hours. Then, the lipopeptide compounds produced in the medium by precipitation with HCl 6M were extracted and dissolved in methanol (50% water; 50% methanol). The antifungal activity of lipopeptide compounds against 5 species of Candida was investigated by well diffusion method, Minimum Inhibitory Concentration (MIC), and Minimum Fungal Concentration (MFC). Also, germ tube production by Candida albicans in tube containing lipopeptide was investigated.
Conclusion The Bacillus amyloliquefaciens M13RW01 lipopeptide metabolites inhibited germ tube production in all C. albicans yeasts, but no inhibitory or fatal effect was observed on other species of Candida. Inhibition zone was not observed around the wells; in all dilutions, Candida yeasts grew. Therefore, minimal inhibitory concentration and minimal fungicidal concentration were not determined.
Keywords:
Bacillus amyloliquefaciens ,
Lipopeptides ,
Candida,
Germ Tube,
Minimal Inhibitory Concentration,
Minimal Fungicidal Concentration,
CITATION LINKS
[1]Williams D, Lewis M. Pathogenesis and treatment of oral candidosis. J Oral Microbiol. 2011;3:1-11.
[2]Baouiri M, Bouhdid S, Harki ELH, Sadiki M, Ouedrhiri W, Ibnsouda SK. Antifungal activity of Bacillus spp. Isolated from Calotropis procera AIT rhizosphere against Candida albicans. Asian J Tradit Med. 2015;8(2):213-7.
[3]Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119-28.
[4]Munimbazi C, Bullerman LB. Isolation and partial characterization of antifungal metabolites of Bacillus pumilus. J Appl Microbiol. 1998;84(6):959-68.
[5]Yuan J, Raza W, Shen Q, Huang Q. Antifungal activity of Bacillus amyloliquefaciens NJN-6 volatile compounds against Fusarium oxysporum f. sp. cubense. Appl Environ Microbiol. 2012;78(16):5942-4.
[6]Milner JL, SiloSuh L, Lee JC, He H, Clardy J, Handelsman J. Production of kanosamine by Bacillus cereus UW85. Appl Environ Microbiol. 1996;62(8):3061-5.
[7]Ranjbariyan A, Shams Ghahfarokhi M, Kalantari S, Razzaghi Abyaneh M. Molecular identification of antagonistic bacteria from Tehran soils and evaluation of their inhibitory activities toward pathogenic fungi. Iran J Biotechnol. 2011;3(3):140-6.
[8]Stein T. Bacillus subtilis antibiotics: Structures syntheses and specific functions. Mol Microbiol. 2005;56(4):845-7.
[9]Caldeira AT, Feio SS, Arteiro JM, Coelho AV, Roseiro JC. Environmental dynamics of Bacillus amyloquefaciens CCMI 1051 antifungal activity under different nitrogen patterns. J Appl Microbiol. 2007;104(3):806-16.
[10]Prist FG, Goodfellow M, Shute LA, Berkeley RCW. Bacillus amyloliquefaciens sp. nov., nom. rev. Int J Syst Bacteriol. 1987;37(1):69-71.
[11]Kerr JR. Bacterial inhibition of fungal growth and pathogenicity. Micro Ecol Health Dis. 1999;11:129-42.
[12]Yoshida S, Hiradate S, Tsukamoto T, Hatakeda K, Shirata A. Antimicrobial activity of culture filtrate of Bacillus amyloliquefaciens RC-2 isolated from mulberry leaves. Phytopathology. 2001;91(2):181-7.
[13]Cho SJ, Lee SK, Cha BJ, Kim YH, Shin KS. Detection and characterization of the gloeosporium gloeosporioides growth inhibitory compound iturin a from bacillus subtilis strain KS03. FEMS Microbiol Lett. 2003;223(1):47-51.
[14]Environment Canada, Health Canada. Framework on the science-based risk assessment of micro-organisms under the Canadian environmental protection act, 1999 [Internet]. Canada: Environment and Climate Change Canada; 2011. [Update 2013 July 30; cited 2011 November 30]. Available from: http://www.ec.gc.ca/subsnouvelles-newsubs/default.asp?lang=En&n=120842D5-1.
[15]Bais HP, Fall R, Vivanco JM. Biocontrol of Bacillus subtilis against infection of Arabidopsis roots by Pseudomonas syringae is facilitated by biofilm formation and surfactin production. Plant Physiol. 2004;134(1):307-19.
[16]Rodrigues L, Banat IM, Teixeira J, Oliveira RR. Biosurfactants: Potential applications in medicine. J Antimicrob Chemother. 2006;57(4):609-18.
[17]Naghdifar SH, Madani M, Ahadi AM. Isolation and identification of inhibitory bacteria against pathogenic fungi from Isfahan using molecular method. J Shahrekord Univ Med Sci. 2016;18(5):83-93. [Persian]
[18]Gong AD, Li HP, Yuan QS, Song XS, Yao W, He WJ, et al. Antagonistic mechanism of iturin A and plipastatin A from Bacillus amyloliquefaciens S76-3 from wheat spikes against Fusarium graminearum. PLoS One. 2015;10(2):e0116871.
[19]Chitarra G, Breeuwer P, Nout MJR, Aelst AC, Rombouts FM, Abee T. Anantifungal compound produced by Bacillus subtilis YM 10-20 inhibits germination of Penicillium roqueforti conidiospores. J Appl Microbiol. 2003;94(2):159-66.
[20]Cui TB, Chai HY, Jiang LX. Isolation and partial characterization of an antifungal protein produced by Bacillus licheniformis BS-3. Molecules. 2012;17(6):7336-47.
[21]Athukorala SN, Fernando WG, Rashid KY. Identification of antifungal antibiotics of Bacillus species isolated from different microhabitats using polymerase chain reaction and MALDI-TOF mass spectrometry. Can J Microbiol. 2009;55(9):1021-32.
[22]Wang J, Zhao S, Qiu J, Zhou Q, Liu X, Xin X, et al. Purification and characterisation of a fungicidal peptide from Bacillus amyloliquefaciens NCPSJ7. J Food Sci. 2017;35(2):113-21.
[23]Magetdana R, Ptak M, Peypoux F, Michel G. Pore-forming properties of iturin A a lipopeptide antibiotic. Biochim Biophys Acta Biomembr. 1985;815(3):405-9.
[24]Maget Dana R, Peypoux F. Iturins a special class of pore-forming lipopeptides: Biological and physicochemical properties. Toxicology. 1994;87(1-3):151-74.
[25]Thimon L, Peypoux F, Wallach, J, Michel G. Effect of the lipopeptide antibiotic, iturin A, on morphology and membrane ultrastructure of yeast cells. FEMS Microbiol Lett. 1995;128(2):101-6.
[26]Fickers P, Guez JS, Damblon C, Leclere V, Bechet M, Jacques P, et al. High-level biosynthesis of the anteiso- C17 isoform of the antibiotic mycosubtilin in Bacillus subtilis and characterization of its candidacidal activity. J Appl Environ Microbiol. 2009;75(13):4636-40.
[27]Tabbene O, Kalai L, Ben Slimene I, Karkouch I, Elkahoui S, Gharbi A, et al. Anti-candida effect of bacillomycin D-like lipopeptides from Bacillus subtilis B38. FEMS Microbiol Lett. 2011;316(2):108-14.
[28]Price NP, Rooney AP, Swezey JL, Perry E, Cohan FM. Mass spectrometric analysis of lipopeptides from Bacillus strains isolated from diverse geographical locations. FEMS Microbiol Lett. 2007;271(1):83-9.
[29]Nasir MN, Thawani A, Kouzayha A, Besson F. Interactions of the natural antimicrobial mycosubtilin with phospholipid membrane models. Colloids Surf B Biointerfaces. 2010;78(1):17-23.
[2]Baouiri M, Bouhdid S, Harki ELH, Sadiki M, Ouedrhiri W, Ibnsouda SK. Antifungal activity of Bacillus spp. Isolated from Calotropis procera AIT rhizosphere against Candida albicans. Asian J Tradit Med. 2015;8(2):213-7.
[3]Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119-28.
[4]Munimbazi C, Bullerman LB. Isolation and partial characterization of antifungal metabolites of Bacillus pumilus. J Appl Microbiol. 1998;84(6):959-68.
[5]Yuan J, Raza W, Shen Q, Huang Q. Antifungal activity of Bacillus amyloliquefaciens NJN-6 volatile compounds against Fusarium oxysporum f. sp. cubense. Appl Environ Microbiol. 2012;78(16):5942-4.
[6]Milner JL, SiloSuh L, Lee JC, He H, Clardy J, Handelsman J. Production of kanosamine by Bacillus cereus UW85. Appl Environ Microbiol. 1996;62(8):3061-5.
[7]Ranjbariyan A, Shams Ghahfarokhi M, Kalantari S, Razzaghi Abyaneh M. Molecular identification of antagonistic bacteria from Tehran soils and evaluation of their inhibitory activities toward pathogenic fungi. Iran J Biotechnol. 2011;3(3):140-6.
[8]Stein T. Bacillus subtilis antibiotics: Structures syntheses and specific functions. Mol Microbiol. 2005;56(4):845-7.
[9]Caldeira AT, Feio SS, Arteiro JM, Coelho AV, Roseiro JC. Environmental dynamics of Bacillus amyloquefaciens CCMI 1051 antifungal activity under different nitrogen patterns. J Appl Microbiol. 2007;104(3):806-16.
[10]Prist FG, Goodfellow M, Shute LA, Berkeley RCW. Bacillus amyloliquefaciens sp. nov., nom. rev. Int J Syst Bacteriol. 1987;37(1):69-71.
[11]Kerr JR. Bacterial inhibition of fungal growth and pathogenicity. Micro Ecol Health Dis. 1999;11:129-42.
[12]Yoshida S, Hiradate S, Tsukamoto T, Hatakeda K, Shirata A. Antimicrobial activity of culture filtrate of Bacillus amyloliquefaciens RC-2 isolated from mulberry leaves. Phytopathology. 2001;91(2):181-7.
[13]Cho SJ, Lee SK, Cha BJ, Kim YH, Shin KS. Detection and characterization of the gloeosporium gloeosporioides growth inhibitory compound iturin a from bacillus subtilis strain KS03. FEMS Microbiol Lett. 2003;223(1):47-51.
[14]Environment Canada, Health Canada. Framework on the science-based risk assessment of micro-organisms under the Canadian environmental protection act, 1999 [Internet]. Canada: Environment and Climate Change Canada; 2011. [Update 2013 July 30; cited 2011 November 30]. Available from: http://www.ec.gc.ca/subsnouvelles-newsubs/default.asp?lang=En&n=120842D5-1.
[15]Bais HP, Fall R, Vivanco JM. Biocontrol of Bacillus subtilis against infection of Arabidopsis roots by Pseudomonas syringae is facilitated by biofilm formation and surfactin production. Plant Physiol. 2004;134(1):307-19.
[16]Rodrigues L, Banat IM, Teixeira J, Oliveira RR. Biosurfactants: Potential applications in medicine. J Antimicrob Chemother. 2006;57(4):609-18.
[17]Naghdifar SH, Madani M, Ahadi AM. Isolation and identification of inhibitory bacteria against pathogenic fungi from Isfahan using molecular method. J Shahrekord Univ Med Sci. 2016;18(5):83-93. [Persian]
[18]Gong AD, Li HP, Yuan QS, Song XS, Yao W, He WJ, et al. Antagonistic mechanism of iturin A and plipastatin A from Bacillus amyloliquefaciens S76-3 from wheat spikes against Fusarium graminearum. PLoS One. 2015;10(2):e0116871.
[19]Chitarra G, Breeuwer P, Nout MJR, Aelst AC, Rombouts FM, Abee T. Anantifungal compound produced by Bacillus subtilis YM 10-20 inhibits germination of Penicillium roqueforti conidiospores. J Appl Microbiol. 2003;94(2):159-66.
[20]Cui TB, Chai HY, Jiang LX. Isolation and partial characterization of an antifungal protein produced by Bacillus licheniformis BS-3. Molecules. 2012;17(6):7336-47.
[21]Athukorala SN, Fernando WG, Rashid KY. Identification of antifungal antibiotics of Bacillus species isolated from different microhabitats using polymerase chain reaction and MALDI-TOF mass spectrometry. Can J Microbiol. 2009;55(9):1021-32.
[22]Wang J, Zhao S, Qiu J, Zhou Q, Liu X, Xin X, et al. Purification and characterisation of a fungicidal peptide from Bacillus amyloliquefaciens NCPSJ7. J Food Sci. 2017;35(2):113-21.
[23]Magetdana R, Ptak M, Peypoux F, Michel G. Pore-forming properties of iturin A a lipopeptide antibiotic. Biochim Biophys Acta Biomembr. 1985;815(3):405-9.
[24]Maget Dana R, Peypoux F. Iturins a special class of pore-forming lipopeptides: Biological and physicochemical properties. Toxicology. 1994;87(1-3):151-74.
[25]Thimon L, Peypoux F, Wallach, J, Michel G. Effect of the lipopeptide antibiotic, iturin A, on morphology and membrane ultrastructure of yeast cells. FEMS Microbiol Lett. 1995;128(2):101-6.
[26]Fickers P, Guez JS, Damblon C, Leclere V, Bechet M, Jacques P, et al. High-level biosynthesis of the anteiso- C17 isoform of the antibiotic mycosubtilin in Bacillus subtilis and characterization of its candidacidal activity. J Appl Environ Microbiol. 2009;75(13):4636-40.
[27]Tabbene O, Kalai L, Ben Slimene I, Karkouch I, Elkahoui S, Gharbi A, et al. Anti-candida effect of bacillomycin D-like lipopeptides from Bacillus subtilis B38. FEMS Microbiol Lett. 2011;316(2):108-14.
[28]Price NP, Rooney AP, Swezey JL, Perry E, Cohan FM. Mass spectrometric analysis of lipopeptides from Bacillus strains isolated from diverse geographical locations. FEMS Microbiol Lett. 2007;271(1):83-9.
[29]Nasir MN, Thawani A, Kouzayha A, Besson F. Interactions of the natural antimicrobial mycosubtilin with phospholipid membrane models. Colloids Surf B Biointerfaces. 2010;78(1):17-23.